Japan Tobacco (JAPAF) 33.9000 $JAPAF
Global Hyperphosphatemia Drugs Market 2015-2019
M2 - Thu Oct 08, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xchtzr/global) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2015-2019" report to their offering. The global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019. Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The market presents huge growth opportunities for vendors because of the growing incidence of hyperphosphatemia and associated high pill burden. Currently, many companies are investing in the discovery and R&D of drugs for the condition. For instance, Tenapor by Ardelyx and AstraZeneca is in phase II developmental stage. The entry of this drug will likely reduce the pill burden associated with the condition. Similarly, RDX002, a type 2a sodium phosphate cotransporter (NaP2b) inhibitor, is being developed by Sanofi. Ardelyx licensed the drug to Sanofi, but retained its co-promotion rights in the US. The launch of novel drug candidates with higher efficacy and safety profile, currently under different stages of development, will contribute to market growth. According to the report, diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The USRDS reported in 2014 that 13.6% adults in the US had CKD, of which diabetes accounted for 44% of kidney failure cases. It also reported in 2012 that high blood pressure led to an increase of 7.7% of kidney failure cases from 2000 to 2010. The International Diabetes Federation reported in 2014 that 387 million people had diabetes in the same year, which is expected to increase by 2035. WHO reported in 2013 that currently over 1 billion people have high blood pressure and about 9.4 million people die from the condition annually worldwide. Further, the report states that non-adherence to treatment regimens is a major challenge faced by the market. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia. Key vendors - Fresenius Medical Care - Keryx Biopharmaceuticals - Sanofi - Shire - Vifor Pharma Other prominent vendors - Alkem - Amgen - Ardelyx - AstraZeneca - Baxter - Bayer - Chugai Pharmaceutical - Japan Tobacco - Kissei Pharmaceutical - Kyowa Hakko Kirin - Mylan - Natco - Novartis - Opko Health - Panion & BF Biotech - Roxane Laboratories - Sandoz - Synthon - Torri Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xchtzr/global
OPK: 8.90 (+0.26), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71), KERX: 4.25 (+0.23)
Japan Tobacco International | JTI Calls for Transparency on Australian 'Plain' Packaging Report
M2 - Tue Oct 06, 6:20AM CDT
The Australian Government has yet to publish its Post-Implementation Review (PIR) into 'plain' packaging for tobacco products, six months after the consultation period ended. The delay has prompted concerns that the authors of the report could be misrepresenting the data and even omitting evidence to ensure that the policy is perceived as a success.
Japan Tobacco International | JT Acquires Natural American Spirit Business outside the United States
M2 - Tue Sep 29, 9:00AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has entered into an agreement with the Reynolds American Inc. group of companies ("RAI"
to acquire the Natural American Spirit business outside the United States which includes the trademarks and all outstanding shares of RAI's subsidiaries outside the U.S. which sell the brand. The transaction is expected to be completed by early 2016.
Reynolds American (RAI) Stock Falls on Natural American Spirit Sale
at The Street - Tue Sep 29, 8:21AM CDT
Reynolds American (RAI) stock is declining in pre-market trading after the company agreed to sell the Natural American Spirit international businesses and trademarks to JT Group (JAPAF) for $5 billion.
RAI: 46.47 (+0.21)
Reynolds American Sells Int'l Rights to Natural American Spirit to Japan Tobacco for $5 Billion
at The Street - Tue Sep 29, 7:57AM CDT
Japan Tobacco, the Tokyo-based buyer of Natural American Spirit, is expanding its premium category with the addition of additive-free and organic cigarettes.
RAI: 46.47 (+0.21)
JT Acquires Natural American Spirit Business Outside the United States
PR Newswire Europe - Tue Sep 29, 5:11AM CDT
TOKYO, September 29, 2015 /PRNewswire/ --
NO BUTTS - CIGARETTE WASTE IS NOW RECYCLABLE IN THE UK
M2 - Mon Sep 28, 10:25AM CDT
A new initiative called the Cigarette Waste Brigade® launches today (28th September 2015) providing people across the UK a way to recycle cigarette butts and associated smokers' waste for the first time. This innovative recycling initiative is a result of a partnership between TerraCycle, a world leader in developing solutions for hard-to-recycle materials and Japan Tobacco International (JTI).
Atopic Dermatitis - Pipeline Review, H1 2015
M2 - Thu Sep 03, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6355p9/atopic_dermatitis) has announced the addition of the "Atopic Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial List of the 60 companies featured in this comprehensive report - AlbireoPharma - Blueberry Therapeutics - ChironWells - Dermira - Eisai - F. Hoffmann-La Roche - Grupo Ferrer Internacional - Han Wha Pharma - IMMD - Japan Tobacco - Kyowa Hakko Kirin - LegoChem Biosciences - MedImmune - Nabriva Therapeutics - Otsuka Holdings - Oxagen - Pharis Biotec - R-Tech Ueno - sterna biologicals - Takeda Pharmaceutical Company - Valeant Pharmaceuticals International - Welichem Biotech - Xencor - Yungjin Pharm Ind. - Ziarco Pharma For more information visit http://www.researchandmarkets.com/research/63..._dermatiti
VRX.TO: 227.56 (+4.67), NBRV: 9.86 (+0.09)
Global E Cigarette & Vaporizer Market 2015 - Analysis & Forecasts to 2025
M2 - Wed Aug 05, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crzt7s/global_e) has announced the addition of the "Global E Cigarette & Vaporizer Market - Analysis & Forecast Through 2015 to 2025" report to their offering. The global e-cigarette market is expected to grow over $50 billion by 2025, at an estimated CAGR of 22.36% from 2015 to 2025. The market will witness a staggering growth until 2017, by when most of the regulatory and policy framework will fall into place. The growth rate will significantly increase thereafter, with significant revenue generation from evolving markets of APAC and Europe. Moreover, while disposable e-cigarettes dominated the global e-cigarette product market till 2014, rechargeable e-cigarettes, followed by personal vaporizers and mods will soon take over the top market positions in terms of revenue generation. The U.S. market will continue with its dominance through the forecast period, however, China is expected to grow at the fastest CAGR to become the second largest revenue generating country by the end of 2025. The report is a meticulous compilation of the different aspects of the e-cigarette industry including the porter's five forces analysis, market dynamics, key consortiums, compliance and regulatory bodies, market breakdown by product types and key geographical locations. The market values form a critical part of the report, herein the revenue generated from sales of e-cigarettes and related products such as cartridges, refills, and e-liquids through retail and online channel is tracked to calculate the market size. While highlighting the key driving and restraining forces for this dynamic market the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the e-cigarette industry. The answers to the following questions can be found in the report: - How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others? - How will the intensity of competitive rivalry evolve through the forecast period? - Which factors will be driving the market through the forecast period? - What factors are currently challenging the e-cigarette industry and how can they be addressed through the forecast period? - Which consortiums are active in the e-cigarette industry? - How are the regulatory bodies such as the Food and Drug Administration (FDA) among others participating in the industry? - Which compliances and certifications are necessary to make a product acceptable among the users (Especially the first time vapers)? - What are the prevalent e-cigarette product types? - What is the average cost of each e-cigarette types along with their key market players? - How will the region home to the e-cigarette manufacturing hub grow through the forecast period? - Which country will lead the global e-cigarette market by the end of the forecast period? - What will be the impact of the EU TPD (European Union Tobacco Product Directive) on the European e-cigarette market? - Who are the key players in the e-cigarette market, especially broken down by start-ups and those operating in China? Key Topics Covered: 1 Report Description 2 Executive Summary 3 Market Entropy 4 Porter's Five Forces Analysis 5 Market Dynamics 6 Global E-Cigarette Consortiums, Compliance, Regulatory, & Certification Bodies 7 Global E-Cigarette Market Analysis, By Product Type 8 Global E-Cigarette Market Analysis, By Geography 9 Key E-Cigarette Company Profiles - Altria Group, Inc. - Ballantyne Brands, Llc. - British American Tobacco Plc. - Clearette Electronic Cigarette Co. - Cloudcig - Dongguan Boluvaper Technology. Co. Ltd. - Feellife Bioscience International Co. Ltd - Fin Branding Group Llc. - First Union - Hubbly Bubbly - International Vapor Group, Inc. - Japan Tobacco, Inc. - Kanger Tech - Kimree - Lekker - Liquideu - Litejoy International Private Limited - Lorillard Inc. - Marlboro - Nice Vapor - Njoy, Inc. - Pacific Smoke International - Philip Morris International, Inc. - Puff Ecig - Puritane - Reynolds American Inc. - Shenzhen Bauway Technology Limited - Simple Vape Co. Ltd. - Smokefree - Smokio - Steamlite - Timya Technology Co. Ltd. - Vape Escapes - Vape Moshi - Vapor Line For more information visit http://www.researchandmarkets.com/research/crzt7s/global_e
PM: 84.07 (-0.08), BTI: 115.33 (+0.02), LO: 71.40 (-0.33), MO: 56.81 (+0.44)
Japan Tobacco International | JTI Results for the 3-month period ended June 30, 2015
M2 - Mon Aug 03, 6:29AM CDT
Pricing drives revenue and profit growth at constant FX
Japan Tobacco International | JT's Consolidated Financial Results for FY2015 Second Quarter
M2 - Mon Aug 03, 6:29AM CDT
Steady profit growth confirmed through solid business performance
Japan Tobacco International | JT completes acquisition of leading US e-cigarette company Logic
M2 - Tue Jul 28, 7:38AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has completed the acquisition of Logic Technology Development LLC ("Logic" , one of the leading US e-cigarette brands. The acquisition was announced in the Company's April 30, 2015 statement, "JT acquires Logic, the leading independent US e-cigarette company." The acquisition is expected to have a minor effect on the Group's consolidated financial performance for the fiscal year 2015.
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 7.21 (+0.08), AMGN: 149.59 (-0.31), GSK: 40.22 (+0.06), AKBA: 10.56 (+0.63), FGEN: 21.77 (+0.22), XLRN: 24.08 (-0.18)
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
New study links smoking to more forms of cancer
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 6:06AM CDT
RAI: 46.47 (+0.21), BTI: 115.33 (+0.02), PM: 84.07 (-0.08), LO: 71.40 (-0.33), MO: 56.81 (+0.44), VGR: 23.36 (+0.04)
Global Hyperphosphatemia Drugs Market 2015-2019
M2 - Thu Oct 08, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xchtzr/global) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2015-2019" report to their offering. The global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019. Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The market presents huge growth opportunities for vendors because of the growing incidence of hyperphosphatemia and associated high pill burden. Currently, many companies are investing in the discovery and R&D of drugs for the condition. For instance, Tenapor by Ardelyx and AstraZeneca is in phase II developmental stage. The entry of this drug will likely reduce the pill burden associated with the condition. Similarly, RDX002, a type 2a sodium phosphate cotransporter (NaP2b) inhibitor, is being developed by Sanofi. Ardelyx licensed the drug to Sanofi, but retained its co-promotion rights in the US. The launch of novel drug candidates with higher efficacy and safety profile, currently under different stages of development, will contribute to market growth. According to the report, diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The USRDS reported in 2014 that 13.6% adults in the US had CKD, of which diabetes accounted for 44% of kidney failure cases. It also reported in 2012 that high blood pressure led to an increase of 7.7% of kidney failure cases from 2000 to 2010. The International Diabetes Federation reported in 2014 that 387 million people had diabetes in the same year, which is expected to increase by 2035. WHO reported in 2013 that currently over 1 billion people have high blood pressure and about 9.4 million people die from the condition annually worldwide. Further, the report states that non-adherence to treatment regimens is a major challenge faced by the market. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia. Key vendors - Fresenius Medical Care - Keryx Biopharmaceuticals - Sanofi - Shire - Vifor Pharma Other prominent vendors - Alkem - Amgen - Ardelyx - AstraZeneca - Baxter - Bayer - Chugai Pharmaceutical - Japan Tobacco - Kissei Pharmaceutical - Kyowa Hakko Kirin - Mylan - Natco - Novartis - Opko Health - Panion & BF Biotech - Roxane Laboratories - Sandoz - Synthon - Torri Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xchtzr/global
OPK: 8.90 (+0.26), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71), KERX: 4.25 (+0.23)
Japan Tobacco International | JTI Calls for Transparency on Australian 'Plain' Packaging Report
M2 - Tue Oct 06, 6:20AM CDT
The Australian Government has yet to publish its Post-Implementation Review (PIR) into 'plain' packaging for tobacco products, six months after the consultation period ended. The delay has prompted concerns that the authors of the report could be misrepresenting the data and even omitting evidence to ensure that the policy is perceived as a success.
Japan Tobacco International | JT Acquires Natural American Spirit Business outside the United States
M2 - Tue Sep 29, 9:00AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has entered into an agreement with the Reynolds American Inc. group of companies ("RAI"
to acquire the Natural American Spirit business outside the United States which includes the trademarks and all outstanding shares of RAI's subsidiaries outside the U.S. which sell the brand. The transaction is expected to be completed by early 2016. Reynolds American (RAI) Stock Falls on Natural American Spirit Sale
at The Street - Tue Sep 29, 8:21AM CDT
Reynolds American (RAI) stock is declining in pre-market trading after the company agreed to sell the Natural American Spirit international businesses and trademarks to JT Group (JAPAF) for $5 billion.
RAI: 46.47 (+0.21)
Reynolds American Sells Int'l Rights to Natural American Spirit to Japan Tobacco for $5 Billion
at The Street - Tue Sep 29, 7:57AM CDT
Japan Tobacco, the Tokyo-based buyer of Natural American Spirit, is expanding its premium category with the addition of additive-free and organic cigarettes.
RAI: 46.47 (+0.21)
JT Acquires Natural American Spirit Business Outside the United States
PR Newswire Europe - Tue Sep 29, 5:11AM CDT
TOKYO, September 29, 2015 /PRNewswire/ --
NO BUTTS - CIGARETTE WASTE IS NOW RECYCLABLE IN THE UK
M2 - Mon Sep 28, 10:25AM CDT
A new initiative called the Cigarette Waste Brigade® launches today (28th September 2015) providing people across the UK a way to recycle cigarette butts and associated smokers' waste for the first time. This innovative recycling initiative is a result of a partnership between TerraCycle, a world leader in developing solutions for hard-to-recycle materials and Japan Tobacco International (JTI).
Atopic Dermatitis - Pipeline Review, H1 2015
M2 - Thu Sep 03, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6355p9/atopic_dermatitis) has announced the addition of the "Atopic Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial List of the 60 companies featured in this comprehensive report - AlbireoPharma - Blueberry Therapeutics - ChironWells - Dermira - Eisai - F. Hoffmann-La Roche - Grupo Ferrer Internacional - Han Wha Pharma - IMMD - Japan Tobacco - Kyowa Hakko Kirin - LegoChem Biosciences - MedImmune - Nabriva Therapeutics - Otsuka Holdings - Oxagen - Pharis Biotec - R-Tech Ueno - sterna biologicals - Takeda Pharmaceutical Company - Valeant Pharmaceuticals International - Welichem Biotech - Xencor - Yungjin Pharm Ind. - Ziarco Pharma For more information visit http://www.researchandmarkets.com/research/63..._dermatiti
VRX.TO: 227.56 (+4.67), NBRV: 9.86 (+0.09)
Global E Cigarette & Vaporizer Market 2015 - Analysis & Forecasts to 2025
M2 - Wed Aug 05, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crzt7s/global_e) has announced the addition of the "Global E Cigarette & Vaporizer Market - Analysis & Forecast Through 2015 to 2025" report to their offering. The global e-cigarette market is expected to grow over $50 billion by 2025, at an estimated CAGR of 22.36% from 2015 to 2025. The market will witness a staggering growth until 2017, by when most of the regulatory and policy framework will fall into place. The growth rate will significantly increase thereafter, with significant revenue generation from evolving markets of APAC and Europe. Moreover, while disposable e-cigarettes dominated the global e-cigarette product market till 2014, rechargeable e-cigarettes, followed by personal vaporizers and mods will soon take over the top market positions in terms of revenue generation. The U.S. market will continue with its dominance through the forecast period, however, China is expected to grow at the fastest CAGR to become the second largest revenue generating country by the end of 2025. The report is a meticulous compilation of the different aspects of the e-cigarette industry including the porter's five forces analysis, market dynamics, key consortiums, compliance and regulatory bodies, market breakdown by product types and key geographical locations. The market values form a critical part of the report, herein the revenue generated from sales of e-cigarettes and related products such as cartridges, refills, and e-liquids through retail and online channel is tracked to calculate the market size. While highlighting the key driving and restraining forces for this dynamic market the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the e-cigarette industry. The answers to the following questions can be found in the report: - How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others? - How will the intensity of competitive rivalry evolve through the forecast period? - Which factors will be driving the market through the forecast period? - What factors are currently challenging the e-cigarette industry and how can they be addressed through the forecast period? - Which consortiums are active in the e-cigarette industry? - How are the regulatory bodies such as the Food and Drug Administration (FDA) among others participating in the industry? - Which compliances and certifications are necessary to make a product acceptable among the users (Especially the first time vapers)? - What are the prevalent e-cigarette product types? - What is the average cost of each e-cigarette types along with their key market players? - How will the region home to the e-cigarette manufacturing hub grow through the forecast period? - Which country will lead the global e-cigarette market by the end of the forecast period? - What will be the impact of the EU TPD (European Union Tobacco Product Directive) on the European e-cigarette market? - Who are the key players in the e-cigarette market, especially broken down by start-ups and those operating in China? Key Topics Covered: 1 Report Description 2 Executive Summary 3 Market Entropy 4 Porter's Five Forces Analysis 5 Market Dynamics 6 Global E-Cigarette Consortiums, Compliance, Regulatory, & Certification Bodies 7 Global E-Cigarette Market Analysis, By Product Type 8 Global E-Cigarette Market Analysis, By Geography 9 Key E-Cigarette Company Profiles - Altria Group, Inc. - Ballantyne Brands, Llc. - British American Tobacco Plc. - Clearette Electronic Cigarette Co. - Cloudcig - Dongguan Boluvaper Technology. Co. Ltd. - Feellife Bioscience International Co. Ltd - Fin Branding Group Llc. - First Union - Hubbly Bubbly - International Vapor Group, Inc. - Japan Tobacco, Inc. - Kanger Tech - Kimree - Lekker - Liquideu - Litejoy International Private Limited - Lorillard Inc. - Marlboro - Nice Vapor - Njoy, Inc. - Pacific Smoke International - Philip Morris International, Inc. - Puff Ecig - Puritane - Reynolds American Inc. - Shenzhen Bauway Technology Limited - Simple Vape Co. Ltd. - Smokefree - Smokio - Steamlite - Timya Technology Co. Ltd. - Vape Escapes - Vape Moshi - Vapor Line For more information visit http://www.researchandmarkets.com/research/crzt7s/global_e
PM: 84.07 (-0.08), BTI: 115.33 (+0.02), LO: 71.40 (-0.33), MO: 56.81 (+0.44)
Japan Tobacco International | JTI Results for the 3-month period ended June 30, 2015
M2 - Mon Aug 03, 6:29AM CDT
Pricing drives revenue and profit growth at constant FX
Japan Tobacco International | JT's Consolidated Financial Results for FY2015 Second Quarter
M2 - Mon Aug 03, 6:29AM CDT
Steady profit growth confirmed through solid business performance
Japan Tobacco International | JT completes acquisition of leading US e-cigarette company Logic
M2 - Tue Jul 28, 7:38AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has completed the acquisition of Logic Technology Development LLC ("Logic"
, one of the leading US e-cigarette brands. The acquisition was announced in the Company's April 30, 2015 statement, "JT acquires Logic, the leading independent US e-cigarette company." The acquisition is expected to have a minor effect on the Group's consolidated financial performance for the fiscal year 2015. Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 7.21 (+0.08), AMGN: 149.59 (-0.31), GSK: 40.22 (+0.06), AKBA: 10.56 (+0.63), FGEN: 21.77 (+0.22), XLRN: 24.08 (-0.18)
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
New study links smoking to more forms of cancer
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 6:06AM CDT
RAI: 46.47 (+0.21), BTI: 115.33 (+0.02), PM: 84.07 (-0.08), LO: 71.40 (-0.33), MO: 56.81 (+0.44), VGR: 23.36 (+0.04)
